Bispecific Antibodies for the Treatment of Multiple Myeloma

被引：0
|
作者：
Scott R. Goldsmith
Shawn Streeter
Fahrettin Covut
机构：
[1] Judy and Bernard Briskin Center for Multiple Myeloma Research,Division of Oncology
[2] City of Hope Comprehensive Cancer Center,undefined
[3] Washington University School of Medicine,undefined
来源：
Current Hematologic Malignancy Reports | 2022年 / 17卷
关键词：
Bispecific antibodies; Bispecific T-cell engagers; Multiple myeloma; Immunotherapy; BCMA;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：286 / 297
页数：11
相关论文
共 50 条
  • [31] Monoclonal antibodies in the treatment of multiple myeloma
    Richardson, Paul G.
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Harousseau, Jean-Luc
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (06) : 745 - 754
  • [32] Bispecific T-cell engagers for treatment of multiple myeloma
    Ravi, Gayathri
    Costa, Luciano J.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S13 - S21
  • [33] Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
    Landgren, Ola
    Nadeem, Omar
    ADVANCES IN THERAPY, 2023, 40 (08) : 3291 - 3303
  • [34] Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies
    Rubinstein, Samuel M.
    Derman, Benjamin A.
    EUROPEAN JOURNAL OF CANCER, 2023, 189
  • [35] Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast
    Ola Landgren
    Omar Nadeem
    Advances in Therapy, 2023, 40 : 3291 - 3303
  • [36] Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis
    Mazahreh, Farah
    Mazahreh, Liyan
    Schinke, Carolina
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    Shaughnessy, John D., Jr.
    Zhan, Fenghuang
    van Rhee, Frits
    Al Hadidi, Samer
    BLOOD ADVANCES, 2023, 7 (13) : 3069 - 3074
  • [37] Current status of bispecific antibodies and CAR-T therapies in multiple myeloma
    Szlasa, Wojciech
    Dybko, Jaroslaw
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 134
  • [38] Risk of Infections Associated with the Use of Bispecific Antibodies in Multiple Myeloma: A Pooled Analysis
    Mazahreh, Farah
    Mazahreh, Liyan
    Schinke, Carolina
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    Shaughnessy, John D., Jr.
    Zhan, Fenghuang
    van Rhee, Frits
    Al Hadidi, Samer
    BLOOD, 2022, 140 : 4378 - 4378
  • [39] Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
    Barila, Gregorio
    Rizzi, Rita
    Zambello, Renato
    Musto, Pellegrino
    PHARMACEUTICALS, 2021, 14 (01) : 1 - 19
  • [40] Efficacy of bispecific antibodies in the treatment of extramedullary disease and high risk cytogenetics in relapsed multiple myeloma: a systematic review
    Vegivinti, Charan
    Santhi, Jaison Lawrence Alexander
    Liu, Lawrence
    Hammami, M. Bakri
    Thakur, Rahul
    Ghimire, Ananta
    Poojary, Nagarathna
    Gopireddy, Murali Mohan Reddy
    Kallamvalappil, Anusha Manoj
    Jitta, Sahas Reddy
    Chintapally, Nikita
    Shah, Nishi
    Janakiram, Murali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S19 - S19
12345